P53 and Thymidine Dimer Induction in Daily Low Emission Broad Band UV Treatment

Abstract

Background/purpose: Phototherapy is widely used as treatment modality for psoriasis. Recently we reported that daily low-dose phototherapy can be effective as treatment for psoriatic patients. To study the carcinogenic effects in patients receiving this treatment, nineteen patients underwent skin biopsies.

Methods: P53 and thymidine dimers were assessed in skin biopsies of psoriasis patients (8 controls, 7 patients with daily low emission broad band UV-treatment, 4 conventional NB-UVB-treatment).

Results: Staining for the presence of p53 in epidermal cells was unremarkable and not significantly different between daily low-dose UV treatment (1/7 = 14.3% p53 positive) and treatment without phototherapy (2/8 = 25.0% p53 positive) (p = 1.0). Thymidine dimers were investigated by FACS analysis. No difference was found in the amount of fluorescence of the cells between daily low-dose UV-treatment and no phototherapy groups (p = 0.189) or in the percentage of dimers found (p = 0.463). A significant (p = 0.006) difference in amount of thymidine dimers was found in patients undergoing conventional TL01 phototherapy compared to the daily low-emission UV-treated group as well as compared to patients not undergoing phototherapy.

Conclusion: These results suggest that treatment of psoriasis patients with daily low-dose UV result in a low carcinogenic risk. Further studies however are needed to confirm these results.

Keywords: p53; Thymidine dimers; Psoriasis; Phototherapy; Low-emission

Introduction

Phototherapy is a widely used treatment for multiple skin diseases, but particularly in psoriasis [1,2]. Many modalities for phototherapy have been used and investigated in the treatment of psoriasis patients: UVA with psoralens (so called local or systemic PUVA), broadband UVB (BB-UVB) and narrowband UVB (NB-UVB). These UV-treatments can be given in different schemes - daily, twice or thrice weekly- and they can be used even in combination with systemic therapy, for instance to enhance the effect of retinoids, or they can be combined with local treatment (e.g. the Goeckerman regimen) [1,3,4].

While phototherapy is often a very effective treatment option in psoriasis patients [1], there are risks involved [5-10]. The well-known acute risks of phototherapy are sunburn and immunosuppression, however many physicians especially worry about a potential carcinogenic risk of this treatment.

Carcinogenic risks

Multiple studies have proven a relatively high carcinogenicity of PUVA-treatment [5,8-10]. This is not surprising since the phototoxic psoralens bind covalently to DNA (so called DNA intercalation) where they function as a source of reactive oxygen species during the UVA exposure. Especially squamous cell carcinomas and their potential precursors, actinic keratoses, have been reported after long-term PUVA treatments.

Several studies have looked into the incidence of skin cancer in patients undergoing Goeckerman regimen (crude coal tar combined with UV-radiation) without being able to ascertain an increased risk of skin malignancies [11,12].

NB-UVB and BB-UVB seem to be relatively safe [13]. No association was found in a study by Hearn et al. [6] which focussed on the UV-induced skin cancer in patients undergoing NB-UVB phototherapy. However, the authors warn that further studies are required to assess the risk, especially if this might be a dose-dependent or cumulative risk, as is the case in PUVA-treatment.

Carcinogenicity is mainly based on the direct genotoxic effects of UV-radiation, and to a lesser extent on the generation of reactive oxygen species (ROS). The latter can directly cause activation of cytochrome c in mitochondria, resulting in apoptosis. The phototoxic effects of UV-radiation on the DNA of cells are the main cause of apoptosis and cellular damage. They are the most investigated mechanism in this context.

UVB-radiation is absorbed by cellular DNA strands which can lead to characteristic C to T transitions. These transitions and thymidine dimers are usually repaired, but after an extensive and frequent photodamage, the cells do not have enough time...
for reparation and some repair errors can be made. A specific UV-signature in the generation of thymidine dimers has been identified in squamous cell carcinomas. This suggests an etiological role of UV-radiation in the development of these skin tumours [8-10,14,15].

Another factor that takes important part in UV-carcinogenesis is protein p53. This is a tumor suppressor gene that plays an essential role in cell cycle control. It can route the cell to apoptosis, repair or cell differentiation [11,16]. It is induced to direct the cell to one of the mentioned pathways when cellular damage by UV-radiation occurred.

Its induction and mutations have been found in several malignant diseases (squamous cell carcinomas, basal cell carcinomas, etc.), precancerous diseases (Bowens disease, actinic keratoses) and benign diseases including psoriasis [17,18]. It has been argued that p53 plays a possible role in the pathogenesis of psoriasis [16,18].

Several studies have shown a significant rise in staining of p53 in psoriatic skin versus normal skin. In non-lesional psoriatic skin, a trend seems to be present in p53 induction, but in two different studies no significant difference could be found [19,20]. However, a significant induction of p53 by UV-exposure was seen [19].

After UV-radiation an induction of p53 can be detected in 12-24 hours, although a slow rise is already distinguishable after 4 hours [21,22].

Treatment with daily low emission UV

Recently, we performed a study with psoriasis patients treated with a daily low dose UV (1 standard erythemal dose (SED) only). In this clinical investigation, a significant drop in PASI-scores was found. This was accomplished in 6 months follow-up. This clinical effect was accompanied by a significant rise in vitamin D 25(OH)D blood concentration [23]. A long-term use phototherapy, albeit with a low UV-emission, however, always raises the question of potential carcinogenic effects. As the main goal of the above mentioned study was to ascertain the efficacy of this therapy for daily use, it is of special importance to evaluate the safety profile of such treatment regimen.

Materials & Methods

Study design was approved by the Medical Ethical Committee of the VU University Medical Center (VUmc) and was performed in accordance to the declaration of Helsinki (2008). The results were gathered in connection with a larger clinical effectiveness study described elsewhere [32].

Patients were randomised in two groups: one group undergoing daily low emission broad band (RB) UV-treatment (Dermasun Helios, Dermasun Medical BV, The Netherlands) and using mometason ointment once daily if they deemed this necessary. The second group only used mometason ointment once daily if necessary. Randomisation took place by choosing a non-marked envelop by patients themselves with a note allocating them to the particular treatment group.

All patients were asked to refrain from sunbathing, use of tanning booth or sunny holidays. Patients did not use oral vitamin D supplements, systemic immunosuppressive medication and did not have a skin malignancy in their medical history.

To measure the DNA damage caused by the daily low emission phototherapy UV-treatment, ten randomly selected patients from each group were asked to allow two skin biopsies of 4 mm after at least 2 months of ongoing treatment. These biopsies were used to measure the presence of p53-mutations and thymidine dimers. Fifteen patients gave their consent, eight patients from the control group and seven patients from the home-treatment group.

As a positive control reference, four psoriasis patients undergoing conventional NB-UVB treatment (during at least two months) given thrice a week underwent skin biopsies as well. All biopsies were taken directly after UV-treatment.

P53-staining was performed routinely at the Pathology department of the VU medical center with monoclonal mouse anti-human p53 protein (Dako, Glostrup, DK) staining both p53 and mutant p53. Sections of adenocarcinoma of the colon were used as p53 positive controls.

P53 induction was visually assessed on two separate occasions in a blinded manner. Histological sections were assessed for an estimated percentage of positive cells and their intensity. A biopsy was deemed positive if 80% of keratinocytes was stained by p53 immunohistochemistry and 30% of those cells had a high-intensity staining. Examples of a p53 positive and negative staining are shown in Figure 1.

Thymidine dimers were measured essentially as described in the protocol of Rouget et al. [24]. In brief: Biopsies were incubated with 0.1% trypsin solution (Gibco, Paysly, UK) at 37°C for 10 minutes and shacked vigorously. After 5 minutes 400 G centrifugation at 4°C the supernatant was discarded and the cells were resuspended with a 50 mM EDTA (Sigma-Aldrich, St., Louis, MO, USA) in PBS solution and fixed by adding 3 volumes of 100% ethanol at -20°C and centrifuged as described above. Cells were incubated for 20 minutes at room temperature with a solution of 0.5% Triton-X100 (Sigma-Aldrich) in 2 N HCl solution. Cells were then washed with a 0.1 M Na2B4O7 (Sigma-Aldrich) and incubated by a 100 ug/ml RNASE A solution (In Vitrogen, Carlsbad, CO, USA) at 37°C for 60 minutes. After washing with FACS-buffer (PBS, 0.1% azide, 0.1% BSA) anti-thymidine dimer antibodies (1:50) (Kamiya Biomedical company, Seattle, WA, USA) were incubated at room temperature for 1 hour. After washing, rabbit anti-mouse IgG-Fitcconjugated antibodies (1:10) (DAKOcytoman, Glostrup, DK) were added and incubated for 4°C in the dark for 30 minutes.

As an internal control, 4 mm biopsies of donated foreskin were irradiated with 2.2 J/cm² at 320 nm (Spectral Luminator; Oriel instruments). Unexposed foreskin was measured in every run as well. Samples treated with only the secondary antibodies were used as a negative control. Samples were measured and analysed using the BD Facscalibur (BD, San Jose, CA, USA). Typical results from control foreskin biopsies and UV radiated foreskin are shown in Figure 2.

Percentage of positive cells was determined by using unexposed foreskin biopsies as negative control. For each experimental run a UV-B exposed foreskin was used as an internal positive control for reproducibility of the assay.
Statistics

Statistical analyses were performed using SPSS (version 20, IBM Corp., Armonk, NY). A p-value <0.05 was considered to indicate statistical significance, a p-value < 0.1 a statistical trend. Outcomes are described by either frequencies and percentages or by median and range. Differences between continuous variables (mean fluorescence and percentage of positive cells) were analysed by the Mann-Whitney U-test, while differences in p53-staining were analysed by the Fisher’s exact test.

Results

In nineteen patients (8 controls without phototherapy, 4 patients with conventional NB-UVB treatment, 7 patients with daily low emission BB UV- treatment) two 4 mm skin biopsies were taken from an area of the body that would normally not be sun exposed during the winter (buttocks, grain and extensor side of the upper arm). Patients undergoing phototherapy were asked to present themselves for the biopsy directly after irradiation. Baseline characteristics of patients can be found in Table 1.
Table 1: Baseline characteristics of included patients.

|                | No Phototherapy (n=8) | Conventional NB-UVB (n=4) | Daily BB-UV (n=7) |
|----------------|-----------------------|---------------------------|-------------------|
| Male, n (%)    | 5 (62.5%)             | 3 (75.0%)                 | 4 (57.1%)         |
| Age, Mean ± SD | 41.5 ± 9.8            | 48.8 ± 13.7               | 43.3 ± 15.1       |

Fitzpatrick Skin Type

|                | No Phototherapy | Conventional NB-UVB | Daily BB-UV |
|----------------|-----------------|---------------------|-------------|
| Type 1, n (%)  | 0 (0%)          | 0 (0%)              | 1 (14.3%)   |
| Type 2, n (%)  | 7 (87.5%)       | 2 (50.0%)           | 6 (85.7%)   |
| Type 3, n (%)  | 1 (12.5%)       | 2 (50.0%)           | 0 (0%)      |
| Treatment time to biopsy, mean | N/A             | 3 months            | 4 months    |

Table 2: Descriptive statistics of p53-mutations and thymidine dimers.

|                | No Phototherapy (n=8) | Conventional NB-UVB (n=4) | Daily BB UV (n=7) |
|----------------|-----------------------|---------------------------|-------------------|
| p53 positive, n (%) | 2 (25.0%)            | Not tested                | 1 (14.3%)        |
| Fluorescence, median [range] | 14.7 [9.2 - 20.4] | 54.1 [27.1 - 179.2] | 20.6 [9.9 - 24.2] |
| Percentage dimers, median [range] | 13.2 [2.5 - 23.3] | 72.3 [57.4 - 80.5] | 14.7 [3.8 - 47.5] |

Staining for the presence of p53 in epidermal cells was not significantly different between daily low-dose UV treatment (1/7=14.3% p53 positive) and treatment without phototherapy (2/8=25.0% p53 positive) (p=1.0, Table 2).

P53 upregulation has been described in prior literature [19,25,26]. P53-staining was therefore not assessed in patient undergoing conventional NB-UVB treatment to minimize the amount of biopsies taken.

Thymidine dimers were investigated by FACS analysis. Although a small up-regulation was seen in the amount of fluorescence of the cells and in the percentage of positive cells in patients undergoing daily low emission BB UV vs no phototherapy, this trend was not significant (Figure 3a & 3b). No difference was found in the amount of fluorescence of the cells between the daily low dose BB UV-treatment and no phototherapy groups (p=0.19) or in the percentage of thymidine dimers found (p=0.46).

To confirm that our method was effective and to clarify the difference with conventional phototherapy, 4 patients undergoing conventional NB-UVB treatment for at least two months were asked to allow a skin biopsy. A significant (p = 0.006) difference was found in these patients compared to the daily low-emission BB UV-treated group as well as compared to patients not undergoing phototherapy.

Discussion

Although the groups in this study were small, the results of our measurements show clear differences. Only a small elevation of thymidine dimers was found in the group receiving daily low emission BB UV treatment compared to patient without any phototherapy. This elevation was, however statistically non-significant. A slight elevation would be expected as patients were receiving any form of phototherapy: a slight UV-damage is a logical result of an effective treatment. However, in comparison with the controls treated with conventional narrowband phototherapy however, the rise in thymidine dimers was remarkably lower. The difference between these groups was statistically significant.

P53-staining was also non-significantly different between patients using mometason only (without UV-therapy) and with daily low-emission UV-therapy. Interestingly, in patients using mometason ointment only the baseline p53 staining was higher than expected. This is in line with prior reports in literature in which a higher p53-activity may be found in psoriatic lesions. Although biopsies were not taken from lesional skin, non-lesional skin seems to have a higher baseline p53 staining as well [19,20].

In light of the results concerning the thymidine dimers, a slight induction of p53 in the skin biopsies in patients undergoing daily low-dose UV treatment was expected. Remarkably, this induction...
was not found, p53-activity was equal in both groups. The evaluation method for p53 staining was semiquantitative: during two separate occasions, a visual estimation on positive staining of p53 and its intensity was done. On one of these occasions, a pathologist took part in the appraisal.

Biopsies taken in the UV-poor winter season from UV-protected skin (buttocks or thighs) in control patients, however showed a relatively high baseline induction of p53. This is in line with previous literature [19,20].

The lack of p53 induction during daily low emission phototherapy has several possible explanations. The induction, if present, should have been demonstrated, as patients undergo daily phototherapy. The peak in p53 induction is after 12-24 hours, but a rise is visible in less than 4 hours [22]. The results therefore could be suggestive to exemplify that low emission broadband phototherapy in a daily regimen can be regarded as a safe treatment. A small, non-significant rise in thymidine dimers (CPD's) was found, suggesting that minimal damage is present and confirms a biologic effect of the low-emissions devices. It might be possible that this damage is so minimal that the NER-pathway is able to rapidly repair the damage. P53 is therefore not induced or so minimally that gross visual detection by an experienced pathologist is not possible.

The clear, gradual elevation of vitamin D (25(OH)D3) over time shows that the daily low-dose UV exposure suffices to induce elevation of vitamin D levels. It therefore seems possible to use UV radiation in a none or minimally damaging fashion, something that has not been studied and reported in prior publications. So far, the assumption has been that treatment with phototherapy, although with high sub-erythematous dosages, obligatorily meant that the production of CPD and p53-induction would follow.

Because the tested groups were small, further investigation to confirm this observation and strengthen these conclusions is needed. As carcinogenic risk is often a cumulative one, it is important to regularly check patients undergoing this treatment modality for development of skin malignancies. Prior studies [28,29] have demonstrated that in particular p53 mutation clones proliferate while exposed to phototherapy, and diminish after UV exposure.

These findings emphasize the potential carcinogenic risk of long-term UV-treatment regimes. However, in this study using a low-dose BB UV-emitting device no significant p53 changes have been found. This suggests a low risk of such unwanted side effects from this device and treatment regime. In light of potential long-term effects of daily low-dose BB UV-radiation, future research should also focus on immunological effects after years. For the time being, a conservative approach seems wise to regularly perform a total skin inspection in patients using this treatment modality in a prolonged fashion to check for possible skin malignancies as it is recommended for all other UV-treatments.

References

1. Chen X, Yang M, Cheng Y, Liu GJ, Zhang M (2013) Narrow-band ultraviolet B phototherapy versus broad-band ultraviolet B or psoralen-ultraviolet A photochemotherapy for psoriasis. Cochrane Database Syst Rev 10: CD009481.
2. Racz E, Preus EP (2015) Phototherapy and photochemotherapy for psoriasis. Dermatol Clin 33(1): 79-89.
3. Baros DN, Gajain VS, Gajain RB, Zrnic B (2014) Comparative analysis of success of psoriasis treatment with standard therapeutic modalities and broadband UV-B therapy in chronic plaque psoriasis: a systematic literature review. J Eur Acad Dermatol Venereol 26(Suppl 3): 22-31.
4. Menter A, Drael DL (1983) The Goeckerman regimen in two psoriasis day care centers. J Am Acad Dermatol 9(1): 59-65.
5. Archier E, Devaux S, Castela E, Gallini A, Aubin F, et al. (2012) Carcinogenic risks of psoralen UV-A therapy and narrowband UV-B therapy in chronic plaque psoriasis: a systematic literature review. J Eur Acad Dermatol Venereol 26(Suppl 3): 22-31.
6. Hearn RM, Kerr AC, Rahim KE, Ferguson J, Dawe RS (2008) Incidence of skin cancers in 3867 patients treated with narrow-band ultraviolet B phototherapy. Br J Dermatol 159(4): 931-935.
7. Kunisada M, Kumimoto H, Ishizaki K, Sakumi K, Nakabeppu Y, et al. (2007) Narrow-band UVB induces more carcinogenic skin tumors than broad-band UBV through the formation of cyclobutane pyrimidine dimer. J Invest Dermatol 127(12): 2865-2871.
8. Stern RS (2012) The risk of squamous cell and basal cell cancer associated with psoralen and ultraviolet A therapy: a 30-year prospective study. J Am Acad Dermatol 66(4): 553-562.
9. Stern RS, Bolshakov S, Nataraj AJ, Ananthaswamy HM (2002) p53 mutation in nonmelanoma skin cancers occurring in psoralen ultraviolet a-treated patients: evidence for heterogeneity and persistent risk of nonmelanoma skin cancer. PUVA Follow-up Study. J Natl Cancer Inst 90(17): 1278-1284.
10. Hannuksela-Svahn A, Pukkala E, Läärä E, Poikolainen K, Karvon J (2000) Psoriasis, its treatment, and cancer in a cohort of Finnish patients. J Invest Dermatol 114(3): 587-590.
11. Hannuksela-Svahn A, Pakkola P, Autio P, Reunala T, Karvon J, et al. (1999) Expression of p53 protein before and after PUVA treatment in psoriasis. Acta Derm Venereol 79(3): 195-199.
12. Larkö O, Swanbeck G (1982) Is UVB treatment of psoriasis safe? A matched control group. Acta Derm Venereol 62(6): 507-512.
13. Mitchell DL (1998) The induction and repair of lesions produced by the photolysis of (6-4) photoproducts in normal and UV-hypersensitive human cells. Mutat Res 194(3): 227-237.
14. Mitchell DL (1998) The relative cytotoxicity of (6-4) photoproducts and cyclobutane dimers in mammalian cells. Photochem Photobiol 48(1): 51-57.
15. Peritz AE, Gasparro FP (1999) Psoriasis, PUVA, and skin cancer--molecular epidemiology: the curious question of T→A transversions. J Invest Dermatol Symp Proc 4(1): 11-16.
16. Soini Y, Kamel D, Pakkola P, Lehto VP, Oikarinen A, et al. (1994) Aberrant accumulation of p53 associates with Ki67 and mitotic count in benign skin lesions. Br J Dermatol 131(4): 514-520.
17. Tadini G, Cerri A, Crosti L, Cattoretti G, Berli E (1989) P53 and oncogenes expression in psoriasis. Acta Derm Venereol Suppl (Stockh) 146: 33-35.

Citation: Franken SM, Spiekstra SW, Witte BI, Pavel S, Rustemeyer T (2016) P53 and Thymidine Dimer Induction in Daily Low Emission Broad Band UV Treatment. MOJ Immunol 4(2): 00123. DOI: 10.15406/moji.2016.04.00123
19. Yazıcı AC, Karabulut AA, Ozen O, Eksioglu M, Ustün H (2007) Expression of p53 in lesions and unaffected skin of patients with plaque-type and guttate psoriasis: a quantitative comparative study. J Dermatol 34(6): 367-374.

20. Baran W, Szeptewkowski JC, Szybejk-Machaj G (2005) Expression of p53 protein in psoriasis, Acta Dermatovenerol. Alp Panonica. Adriat 14(3): 79-83.

21. de Winter S, Vink AA, Roza L, Pavel S (2001) Solar-simulated skin adaptation and its effect on subsequent UV-induced epidermal DNA damage. J Invest Dermatol 117: 678-682.

22. Tjoe M, Smits T, van de Kerkhof PC, Gerritsen MJ (2003) The differential effect of broad band vs narrow band UVB with respect to photodamage and cutaneous inflammation. Exp Dermatol 12: 729-733.

23. Franken SM, Witte B, Pavel S, Rustemeyer T (2014) Psoriasis and daily low-emission phototherapy: effects on disease and vitamin D level. Photodermatol Photoimmunol Photomed 31(2): 83-89.

24. Rouget R, Auclair Y, Loignon M, Affar el B, Drobetsky EA (2008) A sensitive flow cytometry-based nucleotide excision repair assay unexpectedly reveals that mitogen-activated protein kinase signaling does not regulate the removal of UV-induced DNA damage in human cells. J Biol Chem 283(9): 5533-5541.

25. DeSiha B, McKenzie RC, Hunter JA, Norval (2008) M Local effects of TL01 phototherapy in psoriasis. Photodermatol Photoimmunol Photomed 24: 268-269.

26. Jasim ZF, Liao TF, McKenna KE, Robson T, Ouhtit A (2006) The effect of ultra violet B (TL-01) phototherapy on epidermal expression of p53 protein in psoriatic plaques. Photodermatol Photoimmunol Photomed 22(1): 12-17.

27. Roshan A, Jones PH (2012) Chronic low dose UV exposure and p53 mutation: tilting the odds in early epidermal preneoplasia? Int J Radiat Biol 88(10): 682-687.

28. Zhang W, Remeryik F, Zelterman D, Brash DE, Wikonkal NM (2001) Escaping the stem cell compartment: sustained UVB exposure allows p53-mutant keratinocytes to colonize adjacent epidermal proliferating units without incurring additional mutations. Proc Natl Acad Sci U S A 98(24): 13948-13953.

29. Pittelkow MR, Perry HO, Muller SA, Maughan WZ, O’Brien PC (1981) Skin cancer in patients with psoriasis treated with coal tar. A 25-year follow-up study. Arch Dermatol 117(8): 465-468.